{
    "nct_id": "NCT03330028",
    "official_title": "A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology",
    "inclusion_criteria": "1. Age 18 years and above. There will be no upper age restriction.\n2. Eastern Cooperative Oncology Group (ECOG) performance status </= 2.\n3. Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.\n4. Adequate renal, and bone marrow function: a. Leukocytes >= 3,000/uL b. Absolute neutrophil count >= 1,500/uL c. Platelets >= 60,000/Ul d. Serum creatinine <= 1.5 mg/dL\n5. Distant Metastatic Disease of peritoneum: a. Positive peritoneal cytology b. Carcinomatosis on diagnostic laparoscopy or laparotomy.\n6. Completion of preoperative systemic chemotherapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Infections such as pneumonia or wound infections that would preclude protocol therapy.\n2. Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.\n3. Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure.\n4. Subjects deemed unable to comply with study and/or follow-up procedures.\n5. Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity.",
    "miscellaneous_criteria": ""
}